Primary Site >> Stomach Cancer
Gene >> DPYD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Uracil-tegafur in gastric carcinoma: a comprehensive review. PMID: 9704742 Ref: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. PMID: 9893658 |
Ref: Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. PMID: 10213225 Ref: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. PMID: 10473078 Ref: Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. PMID: 10697632 |
Ref: Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. PMID: 10744051 Ref: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. PMID: 10853015 Ref: 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer. PMID: 10953310 Ref: Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. PMID: 10995874 Ref: [Recent advance in gastric cancer chemotherapy]. PMID: 11103235 |
Ref: [Significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced gastric cancers]. PMID: 11383213 Ref: Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion. PMID: 11445849 Ref: High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro. PMID: 11676864 |
Ref: [A complete response after neoadjuvant chemotherapy for advanced gastric cancer with esophageal invasion]. PMID: 11816467 Ref: [Dihydropyrimidine dehydrogenase expression in gastric cancer using anti-human dihydropyrimidine dehydrogenase monoclonal antibody]. PMID: 11865631 Ref: Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma. PMID: 11914904 Ref: Dihydropyrimidine dehydrogenase-related enzymes predict efficacy and adverse reactions of UFT1+cisplatin neoadjuvant chemotherapy for gastric cancer. PMID: 11984087 Ref: Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. PMID: 12014648 Ref: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. PMID: 12111108 Ref: Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. PMID: 12460781 Ref: Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. PMID: 12495474 |
Ref: Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale. PMID: 12655443 Ref: S-1 in gastric cancer: a comprehensive review. PMID: 12775012 Ref: Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines. PMID: 12775023 Ref: Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. PMID: 12775024 Ref: Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study. PMID: 12775025 Ref: Pharmacogenetics of stomach cancer. PMID: 12914384 Ref: Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. PMID: 12942110 Ref: [Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients]. PMID: 14518409 Ref: Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity. PMID: 14556932 |
Ref: Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. PMID: 14654896 Ref: Differences in dihydropyrimidine dehydrogenase activities between gastric and colorectal cancer. PMID: 14992436 Ref: Comparative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in gastric and colorectal cancers. PMID: 15069545 Ref: Preoperative endoscopic analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in gastrointestinal cancer. PMID: 15138561 Ref: The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine. PMID: 15196541 Ref: Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU. PMID: 15224198 Ref: Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. PMID: 15316940 Ref: Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. PMID: 15330198 Ref: Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma. PMID: 15330204 Ref: Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. PMID: 15354215 Ref: Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer. PMID: 15492780 |
Ref: [Assessment of dihydropyrimidine dehydrogenase and thymidylate synthase expression in gastric carcinoma and colonic carcinoma]. PMID: 15751630 Ref: Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. PMID: 15837757 Ref: Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine. PMID: 16080558 Ref: Pharmacogenetics of extraordinary responses to 5-FU/cisplatin chemotherapy in advanced gastric cancer -- report of 2 cases. PMID: 16249645 Ref: Level of 5-fluorodeoxyuridine 5'-monophosphate in cancerous tissue in patients with gastric cancer under preoperative administration of TS-1. A preliminary study. PMID: 16270533 Ref: Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer. PMID: 16302736 Ref: [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function]. PMID: 16315929 Ref: Polymorphism of dihydropyrimidine dehydrogenase (DPYD) Cys29Arg and risk of six malignancies in Japanese. PMID: 17375478 |
Ref: Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. PMID: 16557585 Ref: A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer. PMID: 16619558 Ref: Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency. PMID: 16646564 Ref: [Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients]. PMID: 16685161 Ref: Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. PMID: 16736497 Ref: [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil]. PMID: 16897970 Ref: [Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer]. PMID: 16897978 Ref: Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. PMID: 16897985 Ref: [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients]. PMID: 16965690 Ref: Expression of chemoresistance-related proteins in alpha-fetoprotein-producing adenocarcinoma of the digestive organs. PMID: 16969485 Ref: The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance. PMID: 17089033 Ref: Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. PMID: 17163161 |
Ref: Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil. PMID: 17303323 Ref: Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer. PMID: 17377791 Ref: [The association between DPYD gene polymorphism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colonic carcinoma]. PMID: 17445431 Ref: DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. PMID: 17848752 Ref: [Orotate phosphoribosyltransferase levels in gastric carcinoma and normal gastric mucosa - correlation with thymidylate synthase and dihydropyrimidine dehydrogenase levels and the changes after neoadjuvant chemotherapy]. PMID: 17940372 Ref: Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism. PMID: 17940834 Ref: Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer. PMID: 19262706 |
Ref: Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. PMID: 18231104 Ref: High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. PMID: 18309485 Ref: Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts. PMID: 18506536 Ref: Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. PMID: 18537153 Ref: Challenge for a better combination with basic evidence. PMID: 18553230 Ref: Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts. PMID: 18630517 Ref: Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase. PMID: 18690094 Ref: Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. PMID: 19020767 Ref: The discrepancy in thymidylate synthase and dihydropyrimidine dehydrogenase expression depending on measurement methodologies in stage 4 gastric cancer. PMID: 19102414 |
Ref: Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. PMID: 19084572 Ref: Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. PMID: 19212683 Ref: Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. PMID: 19259093 |
Ref: [Severe bone marrow suppression during adjuvant chemotherapy for gastric cancer by S-1 and its possible relationship to dihydropyrimidine dehydrogenase deficiency]. PMID: 20087047 Ref: Wogonin potentiates the antitumor effects of low dose 5-fluorouracil against gastric cancer through induction of apoptosis by down-regulation of NF-kappaB and regulation of its metabolism. PMID: 20570612 Ref: A case of 5-fluorouracil induced encephalopathy. PMID: 20622967 Ref: Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity. PMID: 20714149 Ref: A predictive factor for the response to S-1 plus cisplatin in gastric cancer. PMID: 20857529 |
Ref: Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. PMID: 21572321 |
Ref: Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. PMID: 22490566 Ref: [A case of recurrent gastric cancer showing partial response to capecitabine/CDDP after treatment with S-1/CDDP]. PMID: 23064073 |
Ref: Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor. PMID: 23064955 Ref: Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. PMID: 23263912 Ref: Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer. PMID: 23532817 Ref: Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers. PMID: 24100378 Ref: [Effect of jianpi liqi recipe on mRNA expressions of TP, DPD, and CYP3A4 in mice with human gastric cancer transplanted tumor]. PMID: 24325062 |
Ref: [Correlated analysis of 5 fluorouracil metabolic enzymes with tumor response after SOX regimen neoadjuvant chemotherapy in advanced gastric cancer]. PMID: 24721353 |
Ref: Comparison of site-specific gene expression levels in primary tumors and synchronous lymph node metastases in advanced gastric cancer. PMID: 24651981 Ref: Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer. PMID: 25112781 Ref: Relationship Between the DPD and TS mRNA Expression and the Response to S-1-Based Chemotherapy and Prognosis in Patients with Advanced Gastric Cancer. PMID: 25388847 Ref: Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer. PMID: 25793299 Ref: Osteogenesis imperfecta, pseudoachalasia, and gastric cancer. PMID: 25874139 |
Ref: [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer]. PMID: 26796803 Ref: High/positive expression of 5-fluorouracil metabolic enzymes predicts better response to S-1 in patients with gastric cancer: a meta-analysis. PMID: 27012156 Ref: ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients. PMID: 27487151 |
Ref: Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. PMID: 27913881 Ref: Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. PMID: 27995989 Ref: The Impact of the Expression Level of Intratumoral Dihydropyrimidine Dehydrogenase on Chemotherapy Sensitivity and Survival of Patients in Gastric Cancer: A Meta-Analysis. PMID: 28255193 Ref: DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. PMID: 29045513 |
Ref: Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial. PMID: 29061504 Ref: TYMS 2R3R polymorphism and DPYD [IVS]14+1G>A gene mutation in Mexican colorectal cancer patients. PMID: 29906295 |